#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=5 .
1-1	0-1	5	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Fibrin Handling for Bioactive Compounds Delivery
2-1	4-10	Fibrin	person	new	coref	5-20
2-2	11-19	Handling	_	_	_	_
2-3	20-23	for	_	_	_	_
2-4	24-33	Bioactive	abstract[4]	new[4]	coref	20-10[0_4]
2-5	34-43	Compounds	substance|abstract[4]	new|new[4]	coref	5-1[9_0]
2-6	44-52	Delivery	abstract[4]	new[4]	_	_

#Text=5.1 .
3-1	53-56	5.1	abstract	new	_	_
3-2	57-58	.	_	_	_	_

#Text=Tuning Fibrin Intrinsic Characteristics
4-1	59-65	Tuning	_	_	_	_
4-2	66-72	Fibrin	abstract|abstract[8]	new|new[8]	coref|coref	20-2|20-2
4-3	73-82	Intrinsic	abstract|abstract[8]	new|new[8]	_	_
4-4	83-98	Characteristics	abstract[8]	new[8]	_	_

#Text=Bioactive compounds including growth factors , cytokines , drugs , and nucleic acids can be easily entrapped in the fibrin matrix by mixing them with fibrinogen or thrombin .
5-1	99-108	Bioactive	substance[9]	giv[9]	coref	8-8[44_9]
5-2	109-118	compounds	substance[9]	giv[9]	_	_
5-3	119-128	including	substance[9]	giv[9]	_	_
5-4	129-135	growth	substance[9]|abstract[10]|abstract[11]	giv[9]|new[10]|new[11]	ana|coref|ana|coref	5-24[0_11]|21-12[129_10]|5-24[0_11]|21-12[129_10]
5-5	136-143	factors	substance[9]|abstract[10]|abstract[11]	giv[9]|new[10]|new[11]	_	_
5-6	144-145	,	substance[9]|abstract[11]	giv[9]|new[11]	_	_
5-7	146-155	cytokines	substance[9]|abstract[11]|substance	giv[9]|new[11]|new	_	_
5-8	156-157	,	substance[9]|abstract[11]	giv[9]|new[11]	_	_
5-9	158-163	drugs	substance[9]|abstract[11]|substance	giv[9]|new[11]|new	_	_
5-10	164-165	,	substance[9]|abstract[11]	giv[9]|new[11]	_	_
5-11	166-169	and	substance[9]|abstract[11]	giv[9]|new[11]	_	_
5-12	170-177	nucleic	substance[9]|abstract[11]|substance[14]	giv[9]|new[11]|new[14]	_	_
5-13	178-183	acids	substance[9]|abstract[11]|substance[14]	giv[9]|new[11]|new[14]	_	_
5-14	184-187	can	_	_	_	_
5-15	188-190	be	_	_	_	_
5-16	191-197	easily	_	_	_	_
5-17	198-207	entrapped	_	_	_	_
5-18	208-210	in	_	_	_	_
5-19	211-214	the	substance[16]	new[16]	coref	6-4[23_16]
5-20	215-221	fibrin	place|substance[16]	giv|new[16]	coref	6-4
5-21	222-228	matrix	substance[16]	new[16]	_	_
5-22	229-231	by	_	_	_	_
5-23	232-238	mixing	_	_	_	_
5-24	239-243	them	abstract	giv	_	_
5-25	244-248	with	_	_	_	_
5-26	249-259	fibrinogen	substance|substance[19]	new|new[19]	coref|coref|coref|coref	6-14|7-3[30_19]|6-14|7-3[30_19]
5-27	260-262	or	substance[19]	new[19]	_	_
5-28	263-271	thrombin	substance[19]|substance	new[19]|new	coref	6-12
5-29	272-273	.	_	_	_	_

#Text=In general , fibrin matrix remains porous regardless the conditions and/or thrombin and fibrinogen ratios .
6-1	274-276	In	_	_	_	_
6-2	277-284	general	abstract	new	_	_
6-3	285-286	,	_	_	_	_
6-4	287-293	fibrin	place|substance[23]	giv|giv[23]	coref|coref|coref|coref	7-13|9-36[0_23]|7-13|9-36[0_23]
6-5	294-300	matrix	substance[23]	giv[23]	_	_
6-6	301-308	remains	_	_	_	_
6-7	309-315	porous	_	_	_	_
6-8	316-326	regardless	_	_	_	_
6-9	327-330	the	abstract[24]	new[24]	_	_
6-10	331-341	conditions	abstract[24]	new[24]	_	_
6-11	342-348	and/or	abstract[24]	new[24]	_	_
6-12	349-357	thrombin	abstract[24]|substance|substance[26]|abstract[28]	new[24]|giv|new[26]|new[28]	coref|coref|coref|coref|coref|coref	7-6|12-10[69_26]|7-6|12-10[69_26]|7-6|12-10[69_26]
6-13	358-361	and	abstract[24]|substance[26]|abstract[28]	new[24]|new[26]|new[28]	_	_
6-14	362-372	fibrinogen	abstract[24]|substance[26]|substance|abstract[28]	new[24]|new[26]|giv|new[28]	coref	7-3[29_0]
6-15	373-379	ratios	abstract[24]|abstract[28]	new[24]|new[28]	_	_
6-16	380-381	.	_	_	_	_

#Text=However , increasing fibrinogen and/or thrombin concentrations densifies the structure of a fibrin gel and reduces its degradation rate , thus slowing down the diffusion of loaded molecules ( e. g. , FGF ) .
7-1	382-389	However	_	_	_	_
7-2	390-391	,	_	_	_	_
7-3	392-402	increasing	substance[29]|substance[30]	giv[29]|giv[30]	_	_
7-4	403-413	fibrinogen	substance[29]|substance[30]	giv[29]|giv[30]	_	_
7-5	414-420	and/or	substance[30]	giv[30]	_	_
7-6	421-429	thrombin	substance[30]|substance|animal[32]	giv[30]|giv|new[32]	coref|coref	12-10|12-10
7-7	430-444	concentrations	substance[30]|animal[32]	giv[30]|new[32]	_	_
7-8	445-454	densifies	_	_	_	_
7-9	455-458	the	abstract[33]	new[33]	_	_
7-10	459-468	structure	abstract[33]	new[33]	_	_
7-11	469-471	of	abstract[33]	new[33]	_	_
7-12	472-473	a	abstract[33]|object[35]	new[33]|new[35]	ana	7-17[0_35]
7-13	474-480	fibrin	abstract[33]|abstract|object[35]	new[33]|giv|new[35]	coref	12-3
7-14	481-484	gel	abstract[33]|object[35]	new[33]|new[35]	_	_
7-15	485-488	and	_	_	_	_
7-16	489-496	reduces	_	_	_	_
7-17	497-500	its	object|abstract[38]	giv|new[38]	coref|coref	13-50|13-50
7-18	501-512	degradation	abstract|abstract[38]	new|new[38]	coref	11-3[61_0]
7-19	513-517	rate	abstract[38]	new[38]	_	_
7-20	518-519	,	_	_	_	_
7-21	520-524	thus	_	_	_	_
7-22	525-532	slowing	_	_	_	_
7-23	533-537	down	_	_	_	_
7-24	538-541	the	abstract[39]	new[39]	coref	11-13[0_39]
7-25	542-551	diffusion	abstract[39]	new[39]	_	_
7-26	552-554	of	abstract[39]	new[39]	_	_
7-27	555-561	loaded	abstract[39]|substance[40]	new[39]|new[40]	appos	7-30[41_40]
7-28	562-571	molecules	abstract[39]|substance[40]	new[39]|new[40]	_	_
7-29	572-573	(	_	_	_	_
7-30	574-576	e.	abstract[41]	giv[41]	ana	8-13[0_41]
7-31	577-579	g.	abstract[41]	giv[41]	_	_
7-32	580-581	,	abstract[41]	giv[41]	_	_
7-33	582-585	FGF	abstract[41]	giv[41]	_	_
7-34	586-587	)	_	_	_	_
7-35	588-589	.	_	_	_	_

#Text=In addition , the release profile of active compounds is affected by their physicochemical properties including partition coefficient , size and functional groups .
8-1	590-592	In	_	_	_	_
8-2	593-601	addition	_	_	_	_
8-3	602-603	,	_	_	_	_
8-4	604-607	the	abstract[43]	new[43]	_	_
8-5	608-615	release	event|abstract[43]	new|new[43]	coref	12-14[71_0]
8-6	616-623	profile	abstract[43]	new[43]	_	_
8-7	624-626	of	abstract[43]	new[43]	_	_
8-8	627-633	active	abstract[43]|substance[44]	new[43]|giv[44]	coref	10-3[58_44]
8-9	634-643	compounds	abstract[43]|substance[44]	new[43]|giv[44]	_	_
8-10	644-646	is	_	_	_	_
8-11	647-655	affected	_	_	_	_
8-12	656-658	by	_	_	_	_
8-13	659-664	their	abstract|abstract[46]	giv|new[46]	coref|coref	9-4[51_0]|9-4[51_0]
8-14	665-680	physicochemical	abstract[46]	new[46]	_	_
8-15	681-691	properties	abstract[46]	new[46]	_	_
8-16	692-701	including	abstract[46]	new[46]	_	_
8-17	702-711	partition	abstract[46]|event|abstract[48]	new[46]|new|new[48]	_	_
8-18	712-723	coefficient	abstract[46]|abstract[48]	new[46]|new[48]	_	_
8-19	724-725	,	abstract[46]	new[46]	_	_
8-20	726-730	size	abstract[46]|quantity	new[46]|new	_	_
8-21	731-734	and	abstract[46]	new[46]	_	_
8-22	735-745	functional	abstract[46]|person[50]	new[46]|new[50]	ana	9-27[0_50]
8-23	746-752	groups	abstract[46]|person[50]	new[46]|new[50]	_	_
8-24	753-754	.	_	_	_	_

#Text=For example , hydrophilic molecules readily leach out ( e. g. , erythromycin , mitomycin C , fluorouracil etc. ) , while hydrophobic molecules , or those which display a strong chemical affinity for the matrix components , are released more gradually ( e. g. , streptomycin , sulfamethoxazole-trimethoprim , cefazolin , enocitabine etc. ) .
9-1	755-758	For	_	_	_	_
9-2	759-766	example	_	_	_	_
9-3	767-768	,	_	_	_	_
9-4	769-780	hydrophilic	substance[51]	giv[51]	coref	35-6[0_51]
9-5	781-790	molecules	substance[51]	giv[51]	_	_
9-6	791-798	readily	_	_	_	_
9-7	799-804	leach	_	_	_	_
9-8	805-808	out	_	_	_	_
9-9	809-810	(	_	_	_	_
9-10	811-813	e.	_	_	_	_
9-11	814-816	g.	_	_	_	_
9-12	817-818	,	_	_	_	_
9-13	819-831	erythromycin	_	_	_	_
9-14	832-833	,	_	_	_	_
9-15	834-843	mitomycin	_	_	_	_
9-16	844-845	C	person	new	_	_
9-17	846-847	,	_	_	_	_
9-18	848-860	fluorouracil	_	_	_	_
9-19	861-865	etc.	_	_	_	_
9-20	866-867	)	_	_	_	_
9-21	868-869	,	_	_	_	_
9-22	870-875	while	_	_	_	_
9-23	876-887	hydrophobic	substance[53]	new[53]	coref	23-12[145_53]
9-24	888-897	molecules	substance[53]	new[53]	_	_
9-25	898-899	,	_	_	_	_
9-26	900-902	or	_	_	_	_
9-27	903-908	those	person	giv	coref	22-7[137_0]
9-28	909-914	which	_	_	_	_
9-29	915-922	display	_	_	_	_
9-30	923-924	a	abstract[55]	new[55]	coref	21-7[126_55]
9-31	925-931	strong	abstract[55]	new[55]	_	_
9-32	932-940	chemical	abstract[55]	new[55]	_	_
9-33	941-949	affinity	abstract[55]	new[55]	_	_
9-34	950-953	for	abstract[55]	new[55]	_	_
9-35	954-957	the	abstract[55]|object[57]	new[55]|new[57]	_	_
9-36	958-964	matrix	abstract[55]|substance|object[57]	new[55]|giv|new[57]	coref	10-21[60_0]
9-37	965-975	components	abstract[55]|object[57]	new[55]|new[57]	_	_
9-38	976-977	,	_	_	_	_
9-39	978-981	are	_	_	_	_
9-40	982-990	released	_	_	_	_
9-41	991-995	more	_	_	_	_
9-42	996-1005	gradually	_	_	_	_
9-43	1006-1007	(	_	_	_	_
9-44	1008-1010	e.	_	_	_	_
9-45	1011-1013	g.	_	_	_	_
9-46	1014-1015	,	_	_	_	_
9-47	1016-1028	streptomycin	_	_	_	_
9-48	1029-1030	,	_	_	_	_
9-49	1031-1060	sulfamethoxazole-trimethoprim	_	_	_	_
9-50	1061-1062	,	_	_	_	_
9-51	1063-1072	cefazolin	_	_	_	_
9-52	1073-1074	,	_	_	_	_
9-53	1075-1086	enocitabine	_	_	_	_
9-54	1087-1091	etc.	_	_	_	_
9-55	1092-1093	)	_	_	_	_
9-56	1094-1095	.	_	_	_	_

#Text=Thus , some compounds need to be modified chemically to become more hydrophobic , resulting in a prolonged retention within the matrix .
10-1	1096-1100	Thus	_	_	_	_
10-2	1101-1102	,	_	_	_	_
10-3	1103-1107	some	substance[58]	giv[58]	coref	12-17[72_58]
10-4	1108-1117	compounds	substance[58]	giv[58]	_	_
10-5	1118-1122	need	_	_	_	_
10-6	1123-1125	to	_	_	_	_
10-7	1126-1128	be	_	_	_	_
10-8	1129-1137	modified	_	_	_	_
10-9	1138-1148	chemically	_	_	_	_
10-10	1149-1151	to	_	_	_	_
10-11	1152-1158	become	_	_	_	_
10-12	1159-1163	more	_	_	_	_
10-13	1164-1175	hydrophobic	_	_	_	_
10-14	1176-1177	,	_	_	_	_
10-15	1178-1187	resulting	_	_	_	_
10-16	1188-1190	in	_	_	_	_
10-17	1191-1192	a	abstract[59]	new[59]	_	_
10-18	1193-1202	prolonged	abstract[59]	new[59]	_	_
10-19	1203-1212	retention	abstract[59]	new[59]	_	_
10-20	1213-1219	within	abstract[59]	new[59]	_	_
10-21	1220-1223	the	abstract[59]|substance[60]	new[59]|giv[60]	coref	12-4[0_60]
10-22	1224-1230	matrix	abstract[59]|substance[60]	new[59]|giv[60]	_	_
10-23	1231-1232	.	_	_	_	_

#Text=Conversely , a proteolytic degradation may be required to speed up the diffusion process .
11-1	1233-1243	Conversely	_	_	_	_
11-2	1244-1245	,	_	_	_	_
11-3	1246-1247	a	abstract[61]	giv[61]	coref	16-16[112_61]
11-4	1248-1259	proteolytic	abstract[61]	giv[61]	_	_
11-5	1260-1271	degradation	abstract[61]	giv[61]	_	_
11-6	1272-1275	may	_	_	_	_
11-7	1276-1278	be	_	_	_	_
11-8	1279-1287	required	_	_	_	_
11-9	1288-1290	to	_	_	_	_
11-10	1291-1296	speed	_	_	_	_
11-11	1297-1299	up	_	_	_	_
11-12	1300-1303	the	abstract[63]	new[63]	_	_
11-13	1304-1313	diffusion	abstract|abstract[63]	giv|new[63]	_	_
11-14	1314-1321	process	abstract[63]	new[63]	_	_
11-15	1322-1323	.	_	_	_	_

#Text=Lastly , fibrin matrix proteolysis through the action of thrombin or plasmin induces the release of entrapped compounds .
12-1	1324-1330	Lastly	_	_	_	_
12-2	1331-1332	,	_	_	_	_
12-3	1333-1339	fibrin	person|substance[66]	giv|new[66]	coref|coref|coref|coref	13-14[0_66]|13-49|13-14[0_66]|13-49
12-4	1340-1346	matrix	substance|substance[66]	giv|new[66]	coref	13-8[74_0]
12-5	1347-1358	proteolysis	substance[66]	new[66]	_	_
12-6	1359-1366	through	substance[66]	new[66]	_	_
12-7	1367-1370	the	substance[66]|abstract[67]	new[66]|new[67]	_	_
12-8	1371-1377	action	substance[66]|abstract[67]	new[66]|new[67]	_	_
12-9	1378-1380	of	substance[66]|abstract[67]	new[66]|new[67]	_	_
12-10	1381-1389	thrombin	substance[66]|abstract[67]|substance|substance[69]	new[66]|new[67]|giv|giv[69]	_	_
12-11	1390-1392	or	substance[66]|abstract[67]|substance[69]	new[66]|new[67]|giv[69]	_	_
12-12	1393-1400	plasmin	substance[66]|abstract[67]|substance[69]|substance	new[66]|new[67]|giv[69]|new	coref	15-5
12-13	1401-1408	induces	_	_	_	_
12-14	1409-1412	the	event[71]	giv[71]	_	_
12-15	1413-1420	release	event[71]	giv[71]	_	_
12-16	1421-1423	of	event[71]	giv[71]	_	_
12-17	1424-1433	entrapped	event[71]|substance[72]	giv[71]|giv[72]	coref	21-23[133_72]
12-18	1434-1443	compounds	event[71]|substance[72]	giv[71]|giv[72]	_	_
12-19	1444-1445	.	_	_	_	_

#Text=In order to restrict this breakdown of the matrix , the co-entrapment of proteolysis inhibitors ( aprotinin , matrix metalloproteinases inhibitors such as galardin ) was investigated . Ahmed et al. identified in their model ( i. e. , chondroprogenitor clonal cell line ) the enzymes responsible for fibrin gel breakdown .
13-1	1446-1448	In	_	_	_	_
13-2	1449-1454	order	_	_	_	_
13-3	1455-1457	to	_	_	_	_
13-4	1458-1466	restrict	_	_	_	_
13-5	1467-1471	this	event[73]	new[73]	coref	13-49[92_73]
13-6	1472-1481	breakdown	event[73]	new[73]	_	_
13-7	1482-1484	of	event[73]	new[73]	_	_
13-8	1485-1488	the	event[73]|substance[74]	new[73]|giv[74]	coref	13-19[0_74]
13-9	1489-1495	matrix	event[73]|substance[74]	new[73]|giv[74]	_	_
13-10	1496-1497	,	_	_	_	_
13-11	1498-1501	the	abstract[75]	new[75]	_	_
13-12	1502-1515	co-entrapment	abstract[75]	new[75]	_	_
13-13	1516-1518	of	abstract[75]	new[75]	_	_
13-14	1519-1530	proteolysis	abstract[75]|substance|object[77]|abstract[78]	new[75]|giv|new[77]|new[78]	ana|ana|ana	13-34[0_78]|13-34[0_78]|13-34[0_78]
13-15	1531-1541	inhibitors	abstract[75]|object[77]|abstract[78]	new[75]|new[77]|new[78]	_	_
13-16	1542-1543	(	abstract[75]|abstract[78]	new[75]|new[78]	_	_
13-17	1544-1553	aprotinin	abstract[75]|abstract[78]|substance	new[75]|new[78]|new	coref	16-6
13-18	1554-1555	,	abstract[75]|abstract[78]	new[75]|new[78]	_	_
13-19	1556-1562	matrix	abstract[75]|abstract[78]|substance|substance[82]	new[75]|new[78]|giv|new[82]	coref|coref	18-9[116_0]|18-9[116_0]
13-20	1563-1581	metalloproteinases	abstract[75]|abstract[78]|abstract|substance[82]	new[75]|new[78]|new|new[82]	coref	14-3[93_0]
13-21	1582-1592	inhibitors	abstract[75]|abstract[78]|substance[82]	new[75]|new[78]|new[82]	_	_
13-22	1593-1597	such	abstract[75]|abstract[78]|substance[82]	new[75]|new[78]|new[82]	_	_
13-23	1598-1600	as	abstract[75]|abstract[78]|substance[82]	new[75]|new[78]|new[82]	_	_
13-24	1601-1609	galardin	abstract[75]|abstract[78]|substance[82]|person	new[75]|new[78]|new[82]|new	coref	16-8[108_0]
13-25	1610-1611	)	abstract[75]|abstract[78]	new[75]|new[78]	_	_
13-26	1612-1615	was	_	_	_	_
13-27	1616-1628	investigated	_	_	_	_
13-28	1629-1630	.	_	_	_	_
13-29	1631-1636	Ahmed	person	new	_	_
13-30	1637-1639	et	_	_	_	_
13-31	1640-1643	al.	_	_	_	_
13-32	1644-1654	identified	_	_	_	_
13-33	1655-1657	in	_	_	_	_
13-34	1658-1663	their	abstract|abstract[86]	giv|new[86]	_	_
13-35	1664-1669	model	abstract[86]	new[86]	_	_
13-36	1670-1671	(	_	_	_	_
13-37	1672-1674	i.	_	_	_	_
13-38	1675-1677	e.	_	_	_	_
13-39	1678-1679	,	_	_	_	_
13-40	1680-1697	chondroprogenitor	object[88]	new[88]	_	_
13-41	1698-1704	clonal	object[88]	new[88]	_	_
13-42	1705-1709	cell	object|object[88]	new|new[88]	_	_
13-43	1710-1714	line	object[88]	new[88]	_	_
13-44	1715-1716	)	_	_	_	_
13-45	1717-1720	the	abstract[89]	new[89]	_	_
13-46	1721-1728	enzymes	abstract[89]	new[89]	_	_
13-47	1729-1740	responsible	abstract[89]	new[89]	_	_
13-48	1741-1744	for	_	_	_	_
13-49	1745-1751	fibrin	abstract|event[92]	giv|giv[92]	coref|coref|coref|coref	14-16|14-16[99_92]|14-16|14-16[99_92]
13-50	1752-1755	gel	object|event[92]	giv|giv[92]	_	_
13-51	1756-1765	breakdown	event[92]	giv[92]	_	_
13-52	1766-1767	.	_	_	_	_

#Text=It appeared that metalloproteinases ( MMP-2 , MMP-3 , MMP-9 ) were secreted concomitantly with fibrin hydrogels breakdown .
14-1	1768-1770	It	_	_	_	_
14-2	1771-1779	appeared	_	_	_	_
14-3	1780-1784	that	abstract[93]	giv[93]	appos	14-8[0_93]
14-4	1785-1803	metalloproteinases	abstract[93]	giv[93]	_	_
14-5	1804-1805	(	_	_	_	_
14-6	1806-1811	MMP-2	object	new	_	_
14-7	1812-1813	,	_	_	_	_
14-8	1814-1819	MMP-3	abstract	giv	ana	15-1
14-9	1820-1821	,	_	_	_	_
14-10	1822-1827	MMP-9	substance	new	_	_
14-11	1828-1829	)	_	_	_	_
14-12	1830-1834	were	_	_	_	_
14-13	1835-1843	secreted	_	_	_	_
14-14	1844-1857	concomitantly	_	_	_	_
14-15	1858-1862	with	_	_	_	_
14-16	1863-1869	fibrin	abstract|event[99]	giv|giv[99]	coref|coref|coref|coref	15-12[105_99]|16-16|15-12[105_99]|16-16
14-17	1870-1879	hydrogels	substance|event[99]	new|giv[99]	coref	16-17
14-18	1880-1889	breakdown	event[99]	giv[99]	_	_
14-19	1890-1891	.	_	_	_	_

#Text=They also noted high plasmin activity in the conditioned media during hydrogel breakdown .
15-1	1892-1896	They	abstract	giv	ana	16-3
15-2	1897-1901	also	_	_	_	_
15-3	1902-1907	noted	_	_	_	_
15-4	1908-1912	high	abstract[102]	new[102]	coref	30-9[194_102]
15-5	1913-1920	plasmin	person|abstract[102]	giv|new[102]	coref	29-8[181_0]
15-6	1921-1929	activity	abstract[102]	new[102]	_	_
15-7	1930-1932	in	abstract[102]	new[102]	_	_
15-8	1933-1936	the	abstract[102]|organization[103]	new[102]|new[103]	_	_
15-9	1937-1948	conditioned	abstract[102]|organization[103]	new[102]|new[103]	_	_
15-10	1949-1954	media	abstract[102]|organization[103]	new[102]|new[103]	_	_
15-11	1955-1961	during	abstract[102]|organization[103]	new[102]|new[103]	_	_
15-12	1962-1970	hydrogel	abstract[102]|organization[103]|substance|event[105]	new[102]|new[103]|new|giv[105]	_	_
15-13	1971-1980	breakdown	abstract[102]|organization[103]|event[105]	new[102]|new[103]|giv[105]	_	_
15-14	1981-1982	.	_	_	_	_

#Text=Then , they demonstrated that aprotinin and galardin , in combination or separately , prevented fibrin hydrogels degradation .
16-1	1983-1987	Then	_	_	_	_
16-2	1988-1989	,	_	_	_	_
16-3	1990-1994	they	abstract	giv	_	_
16-4	1995-2007	demonstrated	_	_	_	_
16-5	2008-2012	that	_	_	_	_
16-6	2013-2022	aprotinin	substance	giv	_	_
16-7	2023-2026	and	_	_	_	_
16-8	2027-2035	galardin	person[108]	giv[108]	_	_
16-9	2036-2037	,	person[108]	giv[108]	_	_
16-10	2038-2040	in	person[108]	giv[108]	_	_
16-11	2041-2052	combination	person[108]|abstract[109]	giv[108]|new[109]	coref	20-7[122_109]
16-12	2053-2055	or	person[108]|abstract[109]	giv[108]|new[109]	_	_
16-13	2056-2066	separately	person[108]|abstract[109]	giv[108]|new[109]	_	_
16-14	2067-2068	,	_	_	_	_
16-15	2069-2078	prevented	_	_	_	_
16-16	2079-2085	fibrin	person|abstract[112]	giv|giv[112]	coref|coref|coref|coref	18-9|34-7[216_112]|18-9|34-7[216_112]
16-17	2086-2095	hydrogels	substance|abstract[112]	giv|giv[112]	_	_
16-18	2096-2107	degradation	abstract[112]	giv[112]	_	_
16-19	2108-2109	.	_	_	_	_

#Text=Figure 4
17-1	2110-2116	Figure	abstract[113]	new[113]	coref	46-1[275_113]
17-2	2117-2118	4	abstract[113]	new[113]	_	_

#Text=summarizes the modifications which can be made on fibrin matrix to regulate the release of entrapped agents .
18-1	2119-2129	summarizes	_	_	_	_
18-2	2130-2133	the	abstract[114]	new[114]	coref	22-4[136_114]
18-3	2134-2147	modifications	abstract[114]	new[114]	_	_
18-4	2148-2153	which	_	_	_	_
18-5	2154-2157	can	_	_	_	_
18-6	2158-2160	be	_	_	_	_
18-7	2161-2165	made	_	_	_	_
18-8	2166-2168	on	_	_	_	_
18-9	2169-2175	fibrin	place|substance[116]	giv|giv[116]	coref|coref	29-33[191_116]|29-33[191_116]
18-10	2176-2182	matrix	substance[116]	giv[116]	_	_
18-11	2183-2185	to	_	_	_	_
18-12	2186-2194	regulate	_	_	_	_
18-13	2195-2198	the	event[117]	new[117]	_	_
18-14	2199-2206	release	event[117]	new[117]	_	_
18-15	2207-2209	of	event[117]	new[117]	_	_
18-16	2210-2219	entrapped	event[117]|person[118]	new[117]|new[118]	coref	20-4[121_118]
18-17	2220-2226	agents	event[117]|person[118]	new[117]|new[118]	_	_
18-18	2227-2228	.	_	_	_	_

#Text=5.2 .
19-1	2229-2232	5.2	abstract	new	_	_
19-2	2233-2234	.	_	_	_	_

#Text=Modifying Fibrin and/or Active Agents for Efficient Combination and Delivery
20-1	2235-2244	Modifying	_	_	_	_
20-2	2245-2251	Fibrin	substance	giv	coref	21-5
20-3	2252-2258	and/or	_	_	_	_
20-4	2259-2265	Active	person[121]	giv[121]	_	_
20-5	2266-2272	Agents	person[121]	giv[121]	_	_
20-6	2273-2276	for	person[121]	giv[121]	_	_
20-7	2277-2286	Efficient	person[121]|abstract[122]	giv[121]|giv[122]	_	_
20-8	2287-2298	Combination	person[121]|abstract[122]	giv[121]|giv[122]	_	_
20-9	2299-2302	and	person[121]	giv[121]	_	_
20-10	2303-2311	Delivery	person[121]|abstract	giv[121]|giv	coref	24-9

#Text=In some instances , fibrin exhibits innate affinity for therapeutics and growth factors but in other cases , the covalent attachment of these compounds to fibrin is considered .
21-1	2312-2314	In	_	_	_	_
21-2	2315-2319	some	time[124]	new[124]	_	_
21-3	2320-2329	instances	time[124]	new[124]	_	_
21-4	2330-2331	,	_	_	_	_
21-5	2332-2338	fibrin	substance	giv	coref	21-26
21-6	2339-2347	exhibits	_	_	_	_
21-7	2348-2354	innate	abstract[126]	giv[126]	_	_
21-8	2355-2363	affinity	abstract[126]	giv[126]	_	_
21-9	2364-2367	for	abstract[126]	giv[126]	_	_
21-10	2368-2380	therapeutics	abstract[126]|substance	giv[126]|new	_	_
21-11	2381-2384	and	abstract[126]	giv[126]	_	_
21-12	2385-2391	growth	abstract[126]|abstract|abstract[129]	giv[126]|new|giv[129]	coref|coref|coref|coref	24-12|24-12[151_129]|24-12|24-12[151_129]
21-13	2392-2399	factors	abstract[126]|abstract[129]	giv[126]|giv[129]	_	_
21-14	2400-2403	but	_	_	_	_
21-15	2404-2406	in	_	_	_	_
21-16	2407-2412	other	abstract[130]	new[130]	_	_
21-17	2413-2418	cases	abstract[130]	new[130]	_	_
21-18	2419-2420	,	_	_	_	_
21-19	2421-2424	the	abstract[132]	new[132]	ana	22-1[0_132]
21-20	2425-2433	covalent	abstract|abstract[132]	new|new[132]	coref	39-3
21-21	2434-2444	attachment	abstract[132]	new[132]	_	_
21-22	2445-2447	of	abstract[132]	new[132]	_	_
21-23	2448-2453	these	abstract[132]|substance[133]	new[132]|giv[133]	coref	40-5[240_133]
21-24	2454-2463	compounds	abstract[132]|substance[133]	new[132]|giv[133]	_	_
21-25	2464-2466	to	abstract[132]|substance[133]	new[132]|giv[133]	_	_
21-26	2467-2473	fibrin	abstract[132]|substance[133]|substance	new[132]|giv[133]|giv	coref	25-13
21-27	2474-2476	is	_	_	_	_
21-28	2477-2487	considered	_	_	_	_
21-29	2488-2489	.	_	_	_	_

#Text=This generally requires chemical modifications with reactive functional groups ( thiols , azides ) allowing a stable association .
22-1	2490-2494	This	abstract	giv	coref	28-20[177_0]
22-2	2495-2504	generally	_	_	_	_
22-3	2505-2513	requires	_	_	_	_
22-4	2514-2522	chemical	abstract[136]	giv[136]	coref	38-9[234_136]
22-5	2523-2536	modifications	abstract[136]	giv[136]	_	_
22-6	2537-2541	with	abstract[136]	giv[136]	_	_
22-7	2542-2550	reactive	abstract[136]|person[137]	giv[136]|giv[137]	coref	33-16[208_137]
22-8	2551-2561	functional	abstract[136]|person[137]	giv[136]|giv[137]	_	_
22-9	2562-2568	groups	abstract[136]|person[137]	giv[136]|giv[137]	_	_
22-10	2569-2570	(	_	_	_	_
22-11	2571-2577	thiols	substance	new	_	_
22-12	2578-2579	,	_	_	_	_
22-13	2580-2586	azides	substance	new	_	_
22-14	2587-2588	)	_	_	_	_
22-15	2589-2597	allowing	_	_	_	_
22-16	2598-2599	a	abstract[140]	new[140]	_	_
22-17	2600-2606	stable	abstract[140]	new[140]	_	_
22-18	2607-2618	association	abstract[140]	new[140]	_	_
22-19	2619-2620	.	_	_	_	_

#Text=Then , reduction/hydrolysis reactions or enzymatic cleavage mediate the release of active molecules .
23-1	2621-2625	Then	_	_	_	_
23-2	2626-2627	,	_	_	_	_
23-3	2628-2648	reduction/hydrolysis	event[141]	new[141]	_	_
23-4	2649-2658	reactions	event[141]	new[141]	_	_
23-5	2659-2661	or	_	_	_	_
23-6	2662-2671	enzymatic	abstract|event[143]	new|new[143]	coref|coref	29-21[0_143]|29-21[0_143]
23-7	2672-2680	cleavage	event[143]	new[143]	_	_
23-8	2681-2688	mediate	_	_	_	_
23-9	2689-2692	the	event[144]	new[144]	ana	24-1[0_144]
23-10	2693-2700	release	event[144]	new[144]	_	_
23-11	2701-2703	of	event[144]	new[144]	_	_
23-12	2704-2710	active	event[144]|substance[145]	new[144]|giv[145]	coref	31-6[0_145]
23-13	2711-2720	molecules	event[144]|substance[145]	new[144]|giv[145]	_	_
23-14	2721-2722	.	_	_	_	_

#Text=It was shown that this approach prolongs the delivery phase of growth factors for example .
24-1	2723-2725	It	event	giv	_	_
24-2	2726-2729	was	_	_	_	_
24-3	2730-2735	shown	_	_	_	_
24-4	2736-2740	that	_	_	_	_
24-5	2741-2745	this	event[147]	new[147]	_	_
24-6	2746-2754	approach	event[147]	new[147]	_	_
24-7	2755-2763	prolongs	_	_	_	_
24-8	2764-2767	the	abstract[149]	new[149]	_	_
24-9	2768-2776	delivery	abstract|abstract[149]	giv|new[149]	_	_
24-10	2777-2782	phase	abstract[149]	new[149]	_	_
24-11	2783-2785	of	abstract[149]	new[149]	_	_
24-12	2786-2792	growth	abstract[149]|abstract|abstract[151]	new[149]|giv|giv[151]	coref|coref	36-15|36-15
24-13	2793-2800	factors	abstract[149]|abstract[151]	new[149]|giv[151]	_	_
24-14	2801-2804	for	abstract[149]|abstract[151]	new[149]|giv[151]	_	_
24-15	2805-2812	example	abstract[149]|abstract[151]	new[149]|giv[151]	_	_
24-16	2813-2814	.	_	_	_	_

#Text=As another illustration , covalently binding of BMP and RGD sequences to fibrin allows interactions with bone marrow stromal cells through integrin surface receptors that triggered downstream signaling pathways .
25-1	2815-2817	As	_	_	_	_
25-2	2818-2825	another	_	_	_	_
25-3	2826-2838	illustration	_	_	_	_
25-4	2839-2840	,	_	_	_	_
25-5	2841-2851	covalently	object[152]	new[152]	coref	39-3[236_152]
25-6	2852-2859	binding	object[152]	new[152]	_	_
25-7	2860-2862	of	_	_	_	_
25-8	2863-2866	BMP	object|abstract[155]	new|new[155]	_	_
25-9	2867-2870	and	abstract[155]	new[155]	_	_
25-10	2871-2874	RGD	abstract|abstract[155]	new|new[155]	_	_
25-11	2875-2884	sequences	abstract[155]	new[155]	_	_
25-12	2885-2887	to	abstract[155]	new[155]	_	_
25-13	2888-2894	fibrin	abstract[155]|substance	new[155]|giv	coref	28-24
25-14	2895-2901	allows	_	_	_	_
25-15	2902-2914	interactions	abstract[157]	new[157]	coref	33-9[206_157]
25-16	2915-2919	with	abstract[157]	new[157]	_	_
25-17	2920-2924	bone	abstract[157]|object[159]	new[157]|new[159]	_	_
25-18	2925-2931	marrow	abstract[157]|animal|object[159]	new[157]|new|new[159]	_	_
25-19	2932-2939	stromal	abstract[157]|object[159]	new[157]|new[159]	_	_
25-20	2940-2945	cells	abstract[157]|object[159]	new[157]|new[159]	_	_
25-21	2946-2953	through	abstract[157]|object[159]	new[157]|new[159]	_	_
25-22	2954-2962	integrin	abstract[157]|object[159]|person|substance[162]	new[157]|new[159]|new|new[162]	_	_
25-23	2963-2970	surface	abstract[157]|object[159]|place|substance[162]	new[157]|new[159]|new|new[162]	coref	43-16
25-24	2971-2980	receptors	abstract[157]|object[159]|substance[162]	new[157]|new[159]|new[162]	_	_
25-25	2981-2985	that	_	_	_	_
25-26	2986-2995	triggered	_	_	_	_
25-27	2996-3006	downstream	abstract[164]	new[164]	_	_
25-28	3007-3016	signaling	abstract|abstract[164]	new|new[164]	_	_
25-29	3017-3025	pathways	abstract[164]	new[164]	_	_
25-30	3026-3027	.	_	_	_	_

#Text=More sophisticated constructions have been tested .
26-1	3028-3032	More	abstract[165]	new[165]	_	_
26-2	3033-3046	sophisticated	abstract[165]	new[165]	_	_
26-3	3047-3060	constructions	abstract[165]	new[165]	_	_
26-4	3061-3065	have	_	_	_	_
26-5	3066-3070	been	_	_	_	_
26-6	3071-3077	tested	_	_	_	_
26-7	3078-3079	.	_	_	_	_

#Text=Starting from BMP-2 , Schmoekel et al. propose a tripartite fusion protein denoted as TG-pl-BMP-2 .
27-1	3080-3088	Starting	_	_	_	_
27-2	3089-3093	from	_	_	_	_
27-3	3094-3099	BMP-2	object	new	coref	30-6
27-4	3100-3101	,	_	_	_	_
27-5	3102-3111	Schmoekel	person	new	_	_
27-6	3112-3114	et	_	_	_	_
27-7	3115-3118	al.	_	_	_	_
27-8	3119-3126	propose	_	_	_	_
27-9	3127-3128	a	object[169]	new[169]	_	_
27-10	3129-3139	tripartite	object[169]	new[169]	_	_
27-11	3140-3146	fusion	abstract|object[169]	new|new[169]	_	_
27-12	3147-3154	protein	object[169]	new[169]	_	_
27-13	3155-3162	denoted	_	_	_	_
27-14	3163-3165	as	_	_	_	_
27-15	3166-3177	TG-pl-BMP-2	_	_	_	_
27-16	3178-3179	.	_	_	_	_

#Text=Under the control of the blood transglutaminase factor XIIIa , the N-terminal transglutaminase substrate domain ( TG ) provides a covalent attachment to fibrin during coagulation .
28-1	3180-3185	Under	_	_	_	_
28-2	3186-3189	the	abstract[170]	new[170]	_	_
28-3	3190-3197	control	abstract[170]	new[170]	_	_
28-4	3198-3200	of	abstract[170]	new[170]	_	_
28-5	3201-3204	the	abstract[170]|abstract[172]	new[170]|new[172]	coref	29-28[189_172]
28-6	3205-3210	blood	abstract[170]|substance|abstract[172]	new[170]|new|new[172]	_	_
28-7	3211-3227	transglutaminase	abstract[170]|abstract[172]	new[170]|new[172]	_	_
28-8	3228-3234	factor	abstract[170]|abstract[172]	new[170]|new[172]	_	_
28-9	3235-3240	XIIIa	abstract[170]|abstract[172]	new[170]|new[172]	_	_
28-10	3241-3242	,	_	_	_	_
28-11	3243-3246	the	abstract[175]	new[175]	appos	28-17[0_175]
28-12	3247-3257	N-terminal	abstract[175]	new[175]	_	_
28-13	3258-3274	transglutaminase	abstract|abstract[175]	new|new[175]	_	_
28-14	3275-3284	substrate	person|abstract[175]	new|new[175]	coref	29-14
28-15	3285-3291	domain	abstract[175]	new[175]	_	_
28-16	3292-3293	(	_	_	_	_
28-17	3294-3296	TG	abstract	giv	coref	29-11[184_0]
28-18	3297-3298	)	_	_	_	_
28-19	3299-3307	provides	_	_	_	_
28-20	3308-3309	a	abstract[177]	giv[177]	_	_
28-21	3310-3318	covalent	abstract[177]	giv[177]	_	_
28-22	3319-3329	attachment	abstract[177]	giv[177]	_	_
28-23	3330-3332	to	abstract[177]	giv[177]	_	_
28-24	3333-3339	fibrin	abstract[177]|substance	giv[177]|giv	coref	29-34
28-25	3340-3346	during	_	_	_	_
28-26	3347-3358	coagulation	event	new	_	_
28-27	3359-3360	.	_	_	_	_

#Text=In addition , upon the action of cell-activated plasmin , the central plasmin substrate domain ( pl ) gives a cleavage site for the local release of the attached growth factor from the fibrin matrix .
29-1	3361-3363	In	_	_	_	_
29-2	3364-3372	addition	_	_	_	_
29-3	3373-3374	,	_	_	_	_
29-4	3375-3379	upon	_	_	_	_
29-5	3380-3383	the	event[180]	new[180]	_	_
29-6	3384-3390	action	event[180]	new[180]	_	_
29-7	3391-3393	of	event[180]	new[180]	_	_
29-8	3394-3408	cell-activated	event[180]|substance[181]	new[180]|giv[181]	coref	29-13[0_181]
29-9	3409-3416	plasmin	event[180]|substance[181]	new[180]|giv[181]	_	_
29-10	3417-3418	,	_	_	_	_
29-11	3419-3422	the	abstract[184]	giv[184]	appos	29-17[0_184]
29-12	3423-3430	central	abstract[184]	giv[184]	_	_
29-13	3431-3438	plasmin	substance|abstract[184]	giv|giv[184]	_	_
29-14	3439-3448	substrate	person|abstract[184]	giv|giv[184]	_	_
29-15	3449-3455	domain	abstract[184]	giv[184]	_	_
29-16	3456-3457	(	_	_	_	_
29-17	3458-3460	pl	abstract	giv	coref	30-3[193_0]
29-18	3461-3462	)	_	_	_	_
29-19	3463-3468	gives	_	_	_	_
29-20	3469-3470	a	place[187]	new[187]	_	_
29-21	3471-3479	cleavage	event|place[187]	giv|new[187]	_	_
29-22	3480-3484	site	place[187]	new[187]	_	_
29-23	3485-3488	for	_	_	_	_
29-24	3489-3492	the	event[188]	new[188]	_	_
29-25	3493-3498	local	event[188]	new[188]	_	_
29-26	3499-3506	release	event[188]	new[188]	_	_
29-27	3507-3509	of	event[188]	new[188]	_	_
29-28	3510-3513	the	event[188]|abstract[189]	new[188]|giv[189]	_	_
29-29	3514-3522	attached	event[188]|abstract[189]	new[188]|giv[189]	_	_
29-30	3523-3529	growth	event[188]|abstract[189]	new[188]|giv[189]	_	_
29-31	3530-3536	factor	event[188]|abstract[189]	new[188]|giv[189]	_	_
29-32	3537-3541	from	event[188]|abstract[189]	new[188]|giv[189]	_	_
29-33	3542-3545	the	event[188]|abstract[189]|substance[191]	new[188]|giv[189]|giv[191]	coref	32-9[201_191]
29-34	3546-3552	fibrin	event[188]|abstract[189]|place|substance[191]	new[188]|giv[189]|giv|giv[191]	coref	31-9
29-35	3553-3559	matrix	event[188]|abstract[189]|substance[191]	new[188]|giv[189]|giv[191]	_	_
29-36	3560-3561	.	_	_	_	_

#Text=Lastly , the C-terminal human BMP-2 domain displays an osteogenic activity .
30-1	3562-3568	Lastly	_	_	_	_
30-2	3569-3570	,	_	_	_	_
30-3	3571-3574	the	abstract[193]	giv[193]	_	_
30-4	3575-3585	C-terminal	abstract[193]	giv[193]	_	_
30-5	3586-3591	human	abstract[193]	giv[193]	_	_
30-6	3592-3597	BMP-2	abstract|abstract[193]	giv|giv[193]	_	_
30-7	3598-3604	domain	abstract[193]	giv[193]	_	_
30-8	3605-3613	displays	_	_	_	_
30-9	3614-3616	an	abstract[194]	giv[194]	_	_
30-10	3617-3627	osteogenic	abstract[194]	giv[194]	_	_
30-11	3628-3636	activity	abstract[194]	giv[194]	_	_
30-12	3637-3638	.	_	_	_	_

#Text=As an alternative to active molecules derivatization , fibrin functionalization can also be achieved .
31-1	3639-3641	As	_	_	_	_
31-2	3642-3644	an	_	_	_	_
31-3	3645-3656	alternative	_	_	_	_
31-4	3657-3659	to	_	_	_	_
31-5	3660-3666	active	abstract[196]	new[196]	_	_
31-6	3667-3676	molecules	substance|abstract[196]	giv|new[196]	_	_
31-7	3677-3691	derivatization	abstract[196]	new[196]	_	_
31-8	3692-3693	,	_	_	_	_
31-9	3694-3700	fibrin	person|abstract[198]	giv|new[198]	coref|coref|coref|coref	32-10|36-15[227_198]|32-10|36-15[227_198]
31-10	3701-3718	functionalization	abstract[198]	new[198]	_	_
31-11	3719-3722	can	_	_	_	_
31-12	3723-3727	also	_	_	_	_
31-13	3728-3730	be	_	_	_	_
31-14	3731-3739	achieved	_	_	_	_
31-15	3740-3741	.	_	_	_	_

#Text=For example , to facilitate BMP interaction with a fibrin matrix , Yang et al.
32-1	3742-3745	For	_	_	_	_
32-2	3746-3753	example	_	_	_	_
32-3	3754-3755	,	_	_	_	_
32-4	3756-3758	to	_	_	_	_
32-5	3759-3769	facilitate	_	_	_	_
32-6	3770-3773	BMP	abstract[199]	new[199]	_	_
32-7	3774-3785	interaction	abstract[199]	new[199]	_	_
32-8	3786-3790	with	abstract[199]	new[199]	_	_
32-9	3791-3792	a	abstract[199]|substance[201]	new[199]|giv[201]	_	_
32-10	3793-3799	fibrin	abstract[199]|place|substance[201]	new[199]|giv|giv[201]	coref	33-4
32-11	3800-3806	matrix	abstract[199]|substance[201]	new[199]|giv[201]	_	_
32-12	3807-3808	,	abstract[199]	new[199]	_	_
32-13	3809-3813	Yang	abstract[199]|person	new[199]|new	_	_
32-14	3814-3816	et	abstract[199]	new[199]	_	_
32-15	3817-3820	al.	abstract[199]	new[199]	_	_

#Text=grafted heparin onto fibrin , this leading to electrostatic interactions between the negative charges of heparin sulfate groups , and the positive charges of BMPs amino acid residues .
33-1	3821-3828	grafted	_	_	_	_
33-2	3829-3836	heparin	substance	new	ana	33-6
33-3	3837-3841	onto	_	_	_	_
33-4	3842-3848	fibrin	object	giv	coref	34-7
33-5	3849-3850	,	_	_	_	_
33-6	3851-3855	this	substance	giv	coref	34-3
33-7	3856-3863	leading	_	_	_	_
33-8	3864-3866	to	_	_	_	_
33-9	3867-3880	electrostatic	abstract[206]	giv[206]	_	_
33-10	3881-3893	interactions	abstract[206]	giv[206]	_	_
33-11	3894-3901	between	abstract[206]	giv[206]	_	_
33-12	3902-3905	the	abstract[206]|object[207]	giv[206]|new[207]	_	_
33-13	3906-3914	negative	abstract[206]|object[207]	giv[206]|new[207]	_	_
33-14	3915-3922	charges	abstract[206]|object[207]	giv[206]|new[207]	_	_
33-15	3923-3925	of	abstract[206]|object[207]	giv[206]|new[207]	_	_
33-16	3926-3933	heparin	abstract[206]|object[207]|person[208]	giv[206]|new[207]|giv[208]	ana	41-1[0_208]
33-17	3934-3941	sulfate	abstract[206]|object[207]|person[208]	giv[206]|new[207]|giv[208]	_	_
33-18	3942-3948	groups	abstract[206]|object[207]|person[208]	giv[206]|new[207]|giv[208]	_	_
33-19	3949-3950	,	abstract[206]	giv[206]	_	_
33-20	3951-3954	and	abstract[206]	giv[206]	_	_
33-21	3955-3958	the	abstract[206]|abstract[209]	giv[206]|new[209]	_	_
33-22	3959-3967	positive	abstract[206]|abstract[209]	giv[206]|new[209]	_	_
33-23	3968-3975	charges	abstract[206]|abstract[209]	giv[206]|new[209]	_	_
33-24	3976-3978	of	abstract[206]|abstract[209]	giv[206]|new[209]	_	_
33-25	3979-3983	BMPs	abstract[206]|abstract[209]|object|substance[212]	giv[206]|new[209]|new|new[212]	coref|coref	34-15[218_0]|34-15[218_0]
33-26	3984-3989	amino	abstract[206]|abstract[209]|substance[212]	giv[206]|new[209]|new[212]	_	_
33-27	3990-3994	acid	abstract[206]|abstract[209]|substance|substance[212]	giv[206]|new[209]|new|new[212]	_	_
33-28	3995-4003	residues	abstract[206]|abstract[209]|substance[212]	giv[206]|new[209]|new[212]	_	_
33-29	4004-4005	.	_	_	_	_

#Text=Interestingly , heparin presence slowed down fibrin degradation , and consequently the release of loaded BMPs .
34-1	4006-4019	Interestingly	_	_	_	_
34-2	4020-4021	,	_	_	_	_
34-3	4022-4029	heparin	plant|substance[214]	giv|new[214]	_	_
34-4	4030-4038	presence	substance[214]	new[214]	_	_
34-5	4039-4045	slowed	_	_	_	_
34-6	4046-4050	down	_	_	_	_
34-7	4051-4057	fibrin	person|abstract[216]	giv|giv[216]	coref|coref	36-13|36-13
34-8	4058-4069	degradation	abstract[216]	giv[216]	_	_
34-9	4070-4071	,	_	_	_	_
34-10	4072-4075	and	_	_	_	_
34-11	4076-4088	consequently	event[217]	new[217]	coref	40-16[243_217]
34-12	4089-4092	the	event[217]	new[217]	_	_
34-13	4093-4100	release	event[217]	new[217]	_	_
34-14	4101-4103	of	event[217]	new[217]	_	_
34-15	4104-4110	loaded	event[217]|object[218]	new[217]|giv[218]	_	_
34-16	4111-4115	BMPs	event[217]|object[218]	new[217]|giv[218]	_	_
34-17	4116-4117	.	_	_	_	_

#Text=Similar observations were made with FGF .
35-1	4118-4125	Similar	abstract[219]	new[219]	_	_
35-2	4126-4138	observations	abstract[219]	new[219]	_	_
35-3	4139-4143	were	_	_	_	_
35-4	4144-4148	made	_	_	_	_
35-5	4149-4153	with	_	_	_	_
35-6	4154-4157	FGF	abstract	giv	_	_
35-7	4158-4159	.	_	_	_	_

#Text=Despite positive effects reported in literature , there are several drawbacks to fibrin or growth factors/proteins functionalization .
36-1	4160-4167	Despite	_	_	_	_
36-2	4168-4176	positive	abstract[221]	new[221]	_	_
36-3	4177-4184	effects	abstract[221]	new[221]	_	_
36-4	4185-4193	reported	_	_	_	_
36-5	4194-4196	in	_	_	_	_
36-6	4197-4207	literature	abstract	new	_	_
36-7	4208-4209	,	_	_	_	_
36-8	4210-4215	there	_	_	_	_
36-9	4216-4219	are	_	_	_	_
36-10	4220-4227	several	abstract[223]	new[223]	_	_
36-11	4228-4237	drawbacks	abstract[223]	new[223]	_	_
36-12	4238-4240	to	abstract[223]	new[223]	_	_
36-13	4241-4247	fibrin	abstract[223]|substance	new[223]|giv	coref	42-8
36-14	4248-4250	or	abstract[223]	new[223]	_	_
36-15	4251-4257	growth	abstract[223]|abstract|abstract[227]	new[223]|giv|giv[227]	ana|ana	37-5[0_227]|37-5[0_227]
36-16	4258-4274	factors/proteins	abstract[223]|abstract|abstract[227]	new[223]|new|giv[227]	_	_
36-17	4275-4292	functionalization	abstract[223]|abstract[227]	new[223]|giv[227]	_	_
36-18	4293-4294	.	_	_	_	_

#Text=First of all , it requires specific skills , and it is time consuming and expensive .
37-1	4295-4300	First	_	_	_	_
37-2	4301-4303	of	_	_	_	_
37-3	4304-4307	all	_	_	_	_
37-4	4308-4309	,	_	_	_	_
37-5	4310-4312	it	abstract	giv	ana	37-11
37-6	4313-4321	requires	_	_	_	_
37-7	4322-4330	specific	abstract[229]	new[229]	_	_
37-8	4331-4337	skills	abstract[229]	new[229]	_	_
37-9	4338-4339	,	_	_	_	_
37-10	4340-4343	and	_	_	_	_
37-11	4344-4346	it	abstract	giv	_	_
37-12	4347-4349	is	_	_	_	_
37-13	4350-4354	time	time	new	_	_
37-14	4355-4364	consuming	_	_	_	_
37-15	4365-4368	and	_	_	_	_
37-16	4369-4378	expensive	_	_	_	_
37-17	4379-4380	.	_	_	_	_

#Text=Furthermore , proteins functionality can be altered by these modifications .
38-1	4381-4392	Furthermore	_	_	_	_
38-2	4393-4394	,	_	_	_	_
38-3	4395-4403	proteins	substance|abstract[233]	new|new[233]	_	_
38-4	4404-4417	functionality	abstract[233]	new[233]	_	_
38-5	4418-4421	can	_	_	_	_
38-6	4422-4424	be	_	_	_	_
38-7	4425-4432	altered	_	_	_	_
38-8	4433-4435	by	_	_	_	_
38-9	4436-4441	these	abstract[234]	giv[234]	coref	45-1[274_234]
38-10	4442-4455	modifications	abstract[234]	giv[234]	_	_
38-11	4456-4457	.	_	_	_	_

#Text=Indeed , covalent binding can mask active sites , thus affecting their bioactivity .
39-1	4458-4464	Indeed	_	_	_	_
39-2	4465-4466	,	_	_	_	_
39-3	4467-4475	covalent	abstract|object[236]	giv|giv[236]	_	_
39-4	4476-4483	binding	object[236]	giv[236]	_	_
39-5	4484-4487	can	_	_	_	_
39-6	4488-4492	mask	_	_	_	_
39-7	4493-4499	active	place[237]	new[237]	ana	39-12[0_237]
39-8	4500-4505	sites	place[237]	new[237]	_	_
39-9	4506-4507	,	_	_	_	_
39-10	4508-4512	thus	_	_	_	_
39-11	4513-4522	affecting	_	_	_	_
39-12	4523-4528	their	place|abstract[239]	giv|new[239]	coref|coref	44-11[273_239]|44-11[273_239]
39-13	4529-4540	bioactivity	abstract[239]	new[239]	_	_
39-14	4541-4542	.	_	_	_	_

#Text=As an alternative , non-modified compounds can be internalized into particles , to slow down their release . Wang et al. developed a sophisticated system which could serve to deliver low-molecular weight hydrophilic drugs .
40-1	4543-4545	As	_	_	_	_
40-2	4546-4548	an	_	_	_	_
40-3	4549-4560	alternative	_	_	_	_
40-4	4561-4562	,	_	_	_	_
40-5	4563-4575	non-modified	substance[240]	giv[240]	ana	40-16[0_240]
40-6	4576-4585	compounds	substance[240]	giv[240]	_	_
40-7	4586-4589	can	_	_	_	_
40-8	4590-4592	be	_	_	_	_
40-9	4593-4605	internalized	_	_	_	_
40-10	4606-4610	into	_	_	_	_
40-11	4611-4620	particles	object	new	_	_
40-12	4621-4622	,	_	_	_	_
40-13	4623-4625	to	_	_	_	_
40-14	4626-4630	slow	_	_	_	_
40-15	4631-4635	down	_	_	_	_
40-16	4636-4641	their	substance|event[243]	giv|giv[243]	coref|coref	43-7[0_243]|43-7[0_243]
40-17	4642-4649	release	event[243]	giv[243]	_	_
40-18	4650-4651	.	_	_	_	_
40-19	4652-4656	Wang	person	new	_	_
40-20	4657-4659	et	_	_	_	_
40-21	4660-4663	al.	_	_	_	_
40-22	4664-4673	developed	_	_	_	_
40-23	4674-4675	a	abstract[245]	new[245]	_	_
40-24	4676-4689	sophisticated	abstract[245]	new[245]	_	_
40-25	4690-4696	system	abstract[245]	new[245]	_	_
40-26	4697-4702	which	_	_	_	_
40-27	4703-4708	could	_	_	_	_
40-28	4709-4714	serve	_	_	_	_
40-29	4715-4717	to	_	_	_	_
40-30	4718-4725	deliver	_	_	_	_
40-31	4726-4739	low-molecular	substance[247]	new[247]	_	_
40-32	4740-4746	weight	abstract|substance[247]	new|new[247]	_	_
40-33	4747-4758	hydrophilic	substance[247]	new[247]	_	_
40-34	4759-4764	drugs	substance[247]	new[247]	_	_
40-35	4765-4766	.	_	_	_	_

#Text=They used an antithrombosis drug ( i. e. , Tirofiban® ) as a drug model .
41-1	4767-4771	They	person	giv	_	_
41-2	4772-4776	used	_	_	_	_
41-3	4777-4779	an	substance[249]	new[249]	appos	41-10[0_249]
41-4	4780-4794	antithrombosis	substance[249]	new[249]	_	_
41-5	4795-4799	drug	substance[249]	new[249]	_	_
41-6	4800-4801	(	_	_	_	_
41-7	4802-4804	i.	_	_	_	_
41-8	4805-4807	e.	_	_	_	_
41-9	4808-4809	,	_	_	_	_
41-10	4810-4820	Tirofiban®	substance	giv	coref	41-14
41-11	4821-4822	)	_	_	_	_
41-12	4823-4825	as	_	_	_	_
41-13	4826-4827	a	_	_	_	_
41-14	4828-4832	drug	substance	giv	coref	43-6
41-15	4833-4838	model	_	_	_	_
41-16	4839-4840	.	_	_	_	_

#Text=Drug-loaded liposomes were first encapsulated in a fibrin gel , and then combined to chitosan .
42-1	4841-4852	Drug-loaded	object[252]	new[252]	coref	43-19[0_252]
42-2	4853-4862	liposomes	object[252]	new[252]	_	_
42-3	4863-4867	were	_	_	_	_
42-4	4868-4873	first	_	_	_	_
42-5	4874-4886	encapsulated	_	_	_	_
42-6	4887-4889	in	_	_	_	_
42-7	4890-4891	a	object[254]	new[254]	_	_
42-8	4892-4898	fibrin	abstract|object[254]	giv|new[254]	coref	43-33
42-9	4899-4902	gel	object[254]	new[254]	_	_
42-10	4903-4904	,	_	_	_	_
42-11	4905-4908	and	_	_	_	_
42-12	4909-4913	then	_	_	_	_
42-13	4914-4922	combined	_	_	_	_
42-14	4923-4925	to	_	_	_	_
42-15	4926-4934	chitosan	substance	new	coref	43-25
42-16	4935-4936	.	_	_	_	_

#Text=To document/characterize the in vitro drug release profile , different parameters were studied including the surface charge of liposomes , the pore size of chitosan structure , and the crosslinking degree of fibrin gels .
43-1	4937-4939	To	_	_	_	_
43-2	4940-4961	document/characterize	_	_	_	_
43-3	4962-4965	the	abstract[258]	new[258]	_	_
43-4	4966-4968	in	abstract[258]	new[258]	_	_
43-5	4969-4974	vitro	abstract[258]	new[258]	_	_
43-6	4975-4979	drug	substance|abstract[258]	giv|new[258]	_	_
43-7	4980-4987	release	event|abstract[258]	giv|new[258]	_	_
43-8	4988-4995	profile	abstract[258]	new[258]	_	_
43-9	4996-4997	,	_	_	_	_
43-10	4998-5007	different	abstract[259]	new[259]	_	_
43-11	5008-5018	parameters	abstract[259]	new[259]	_	_
43-12	5019-5023	were	_	_	_	_
43-13	5024-5031	studied	_	_	_	_
43-14	5032-5041	including	_	_	_	_
43-15	5042-5045	the	abstract[261]	new[261]	_	_
43-16	5046-5053	surface	place|abstract[261]	giv|new[261]	_	_
43-17	5054-5060	charge	abstract[261]	new[261]	_	_
43-18	5061-5063	of	abstract[261]	new[261]	_	_
43-19	5064-5073	liposomes	abstract[261]|object	new[261]|giv	_	_
43-20	5074-5075	,	_	_	_	_
43-21	5076-5079	the	abstract[264]	new[264]	_	_
43-22	5080-5084	pore	abstract|abstract[264]	new|new[264]	_	_
43-23	5085-5089	size	abstract[264]	new[264]	_	_
43-24	5090-5092	of	abstract[264]	new[264]	_	_
43-25	5093-5101	chitosan	abstract[264]|person|abstract[266]	new[264]|giv|new[266]	_	_
43-26	5102-5111	structure	abstract[264]|abstract[266]	new[264]|new[266]	_	_
43-27	5112-5113	,	_	_	_	_
43-28	5114-5117	and	_	_	_	_
43-29	5118-5121	the	abstract[268]	new[268]	_	_
43-30	5122-5134	crosslinking	abstract|abstract[268]	new|new[268]	_	_
43-31	5135-5141	degree	abstract[268]	new[268]	_	_
43-32	5142-5144	of	abstract[268]	new[268]	_	_
43-33	5145-5151	fibrin	abstract[268]|person|object[270]	new[268]|giv|new[270]	_	_
43-34	5152-5156	gels	abstract[268]|object[270]	new[268]|new[270]	_	_
43-35	5157-5158	.	_	_	_	_

#Text=All these experimental conditions offered different prolonged releases without altering the composite bioactivity .
44-1	5159-5162	All	abstract[271]	new[271]	_	_
44-2	5163-5168	these	abstract[271]	new[271]	_	_
44-3	5169-5181	experimental	abstract[271]	new[271]	_	_
44-4	5182-5192	conditions	abstract[271]	new[271]	_	_
44-5	5193-5200	offered	_	_	_	_
44-6	5201-5210	different	abstract[272]	new[272]	_	_
44-7	5211-5220	prolonged	abstract[272]	new[272]	_	_
44-8	5221-5229	releases	abstract[272]	new[272]	_	_
44-9	5230-5237	without	_	_	_	_
44-10	5238-5246	altering	_	_	_	_
44-11	5247-5250	the	abstract[273]	giv[273]	_	_
44-12	5251-5260	composite	abstract[273]	giv[273]	_	_
44-13	5261-5272	bioactivity	abstract[273]	giv[273]	_	_
44-14	5273-5274	.	_	_	_	_

#Text=All these modifications are summarized in
45-1	5275-5278	All	abstract[274]	giv[274]	_	_
45-2	5279-5284	these	abstract[274]	giv[274]	_	_
45-3	5285-5298	modifications	abstract[274]	giv[274]	_	_
45-4	5299-5302	are	_	_	_	_
45-5	5303-5313	summarized	_	_	_	_
45-6	5314-5316	in	_	_	_	_

#Text=Figure 4
46-1	5317-5323	Figure	abstract[275]	giv[275]	_	_
46-2	5324-5325	4	abstract[275]	giv[275]	_	_

#Text=.
47-1	5326-5327	.	_	_	_	_
